ライフサイエンスコーパス: simian immunodeficiency virus

1 uent mucosal challenge with a chimeric human/simian immunodeficiency virus.

2 induction by HIV, murine leukemia virus, and simian immunodeficiency virus.

3 , some of which may be linked to response to simian immunodeficiency virus.

4 1) that inhibit the replication of human and simian immunodeficiency viruses.

5 d with non-MTB bacterial pathogens, nor with simian immunodeficiency virus alone.

6 cells to prevent the early dissemination of simian immunodeficiency virus and perhaps clear residual

7 NK cell activity in cells infected with HIV, simian immunodeficiency virus, and other persistent viru

8 s equivalent or reduced effects on divergent simian immunodeficiency viruses, and does not inhibit ot

9 s that were molecularly engineered with anti-simian immunodeficiency virus (anti-SIV) activity into r

10 strict retroviral infections such as HIV and simian immunodeficiency virus by limiting cellular dNTPs

11 nated monkeys to clear a subsequent virulent simian immunodeficiency virus challenge.

12 hether it functions within its native Gag in simian immunodeficiency virus cpzGAB2 (SIVcpzGAB2) or SI

13 ue lungs by DeltasigH was not reactivated by simian immunodeficiency virus, despite high viral levels

14 s of lentiviruses, including HIV-2 and other simian immunodeficiency viruses, encode accessory genes

15 enhanced by substituting naturally occurring simian immunodeficiency virus Env residues at position 3

16 Applied to the immune escape of a simian immunodeficiency virus epitope, model predictions

17 HIV-2 and some simian immunodeficiency viruses express viral protein X

18 the result of cross-species transmission of simian immunodeficiency virus from chimpanzees (SIVcpz).

19 immunodeficiency virus type 2 (HIV-2) and a simian immunodeficiency virus from rhesus macaques (SIVm

20 evant rhesus macaque model of infection with simian immunodeficiency virus from sooty mangabey (SIVsm

21 via distinct zoonotic transmission events of simian immunodeficiency viruses from chimpanzees and soo

22 en widely accepted to be the consequences of simian immunodeficiency viruses from wild chimpanzees (S

23 Immunogenicity of a 300-aa portion of the simian immunodeficiency virus Gag protein expressed in m

24 To address this question, we have analyzed simian immunodeficiency virus Gag-specific CD8(+) T cell

25 by electroporation (DNA/EP), all expressing Simian immunodeficiency virus group specific antigen/tra

26 that the vpr gene from different strains of Simian Immunodeficiency Virus has adapted to the polymor

27 Chronic human immunodeficiency virus and simian immunodeficiency virus (HIV and SIV) infections a

28 sylation of the envelope spikes of human and simian immunodeficiency virus (HIV and SIV) is an import

29 The cytoplasmic tails of human and simian immunodeficiency virus (HIV and SIV, respectively

30 d rhesus macaques infected with the human or simian immunodeficiency virus (HIV or SIV), respectively

31 thway in human immunodeficiency virus type 1/simian immunodeficiency virus (HIV-1/SIV) infection rema

32 izing antibodies (NAbs) early after human or simian immunodeficiency virus (HIV/SIV) infection are no

33 or site of inflammation during chronic human/simian immunodeficiency virus (HIV/SIV) infection.

34 st range mutant human immunodeficiency virus/simian immunodeficiency virus (HIV/SIV) recombinant prim

35 ence of a distinct subpopulation of human or simian immunodeficiency virus (HIV/SIV) sequences within

36 The overall CD8 T cell response to human/simian immunodeficiency virus (HIV/SIV) targets a collec

37 rogrammed Death 1 (PD-1) expression by human/simian immunodeficiency virus (HIV/SIV)-specific CD8 T c

38 Human and simian immunodeficiency viruses (HIV and SIV) exploit fo

39 ant for controlling replication of human and simian immunodeficiency viruses (HIV and SIV).

40 requency of spontaneous control of human and simian immunodeficiency viruses (HIV and SIV).

41 Established infections with the human and simian immunodeficiency viruses (HIV and SIV, respective

42 emained at protective levels despite chronic simian immunodeficiency virus/HIV-induced immunosuppress

43 on of lentiviruses such as HIV-1, HIV-2, and simian immunodeficiency virus in macrophages by enzymati

44 However, simian immunodeficiency virus-induced reactivation of la

45 PH, in mice with hypoxia-induced PH, and in Simian immunodeficiency virus-infected macaques, in whic

46 Notably, evaluation of simian immunodeficiency virus-infected nonhuman primates

47 We therefore used antifibrotic therapy in simian immunodeficiency virus-infected rhesus macaques t

48 we analyzed archival brain specimens from 20 simian immunodeficiency virus-infected rhesus with AIDS

49 the gut is well-maintained in nonpathogenic simian immunodeficiency virus infection as well as HIV-1

50 ontaining protein 1 (SAMHD1) restricts human/simian immunodeficiency virus infection in certain cell

51 dge gained from studies in non-human primate simian immunodeficiency virus infection models.

52 tection from human immunodeficiency virus or simian immunodeficiency virus infection remain incomplet

53 Despite acute simian immunodeficiency virus infection, all animals rem

54 Here we show that in simian immunodeficiency virus infection, these cells are

55 agrees well with the experimental data from simian immunodeficiency virus infections in morphine-add

56 tudying adaptation to host SAMHD1 in natural simian immunodeficiency virus infections of African Gree

57 s among uninfected animals exposed to HIV or simian immunodeficiency virus, irrespective of route of

58 ng limiting-dose inoculations with a diverse simian immunodeficiency virus isolate stock may increase

59 smission in nonhuman primates with a diverse simian immunodeficiency virus isolate stock may increase

60 of neutralization-resistant HIV-1, HIV-2 and simian immunodeficiency virus isolates, including a comp

61 ctious molecular clones from two widely used simian immunodeficiency virus lineages (SIVmac251 and SI

62 an immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus mac239 (SIV(mac239)) repli

63 te that a single injection of rAd26 encoding simian immunodeficiency virus mac239 (SIVmac239) Gag on

64 We used the simian immunodeficiency virus mac251 (SIV(mac251)) macaq

65 and our current understanding comes from the simian immunodeficiency virus macaque model.

66 The Nef proteins of human and simian immunodeficiency viruses manipulate infected CD4(

67 udy, we demonstrated that HIV-1 NL4-3 with a simian immunodeficiency virus mne (SIVmne) vif gene subs

68 Simian immunodeficiency virus of chimpanzees (SIVcpz) is

69 an immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus of macaques (SIV(MAC) and

70 l reservoir during infections with HIV-1 and simian immunodeficiency virus of macaques (SIVmac).

71 degradation and inhibited wild-type SIVmac (simian immunodeficiency virus of macaques) infection of

72 iral protein X (Vpx) proteins from the major simian immunodeficiency virus of rhesus macaque, sooty m

73 s type 1 (HIV-1), but in lentiviruses of the simian immunodeficiency virus of sooty mangabey (SIVsm)-

74 the differences between the Env proteins of simian immunodeficiency virus/simian HIV (SIV/SHIV) stoc

75 ugh nonhuman primate studies have shown that simian immunodeficiency virus/simian-human immunodeficie

76 rhesus macaques infected with the pathogenic simian immunodeficiency virus SIV(mac251) and treated wi

77 exposed them intrarectally to a dose of the simian immunodeficiency virus SIV(mac251) that transmits

78 However, with the exception of simian immunodeficiency virus (SIV) (family Retroviridae

79 imian-human immunodeficiency virus (SHIV) or simian immunodeficiency virus (SIV) acquisition in three

80 ine-induced antibodies to capture infectious simian immunodeficiency virus (SIV) and explored the rel

81 We found here that an ALVAC-simian immunodeficiency virus (SIV) and gp120 alum (ALVA

82 A hallmark of pathogenic simian immunodeficiency virus (SIV) and human immunodefi

83 n monkeys (AGMs) are naturally infected with simian immunodeficiency virus (SIV) at high prevalence l

84 infection and, to a lesser extent, HIV-2 and simian immunodeficiency virus (SIV) because of their vir

85 nodes from pigtailed macaques infected with simian immunodeficiency virus (SIV) carrying HIV-1 rever

86 e that showed significant protection against simian immunodeficiency virus (SIV) challenge and sugges

87 We compared the relative efficacies against simian immunodeficiency virus (SIV) challenge of three v

88 e route on protection against a heterologous simian immunodeficiency virus (SIV) challenge.

89 confer partial protection against stringent simian immunodeficiency virus (SIV) challenges in rhesus

90 fully heterologous, neutralization-resistant simian immunodeficiency virus (SIV) challenges in rhesus

91 a late boost and three additional series of simian immunodeficiency virus (SIV) challenges in seven

92 HIV-2 and simian immunodeficiency virus (SIV) counteract this rest

93 cytes (CD8TL) are associated with control of simian immunodeficiency virus (SIV) despite extensive ne

94 se macaques consistently displayed low-level simian immunodeficiency virus (SIV) diversity, which was

95 ls (DCs) and B cells, as an adjuvant for our simian immunodeficiency virus (SIV) DNA vaccine in rhesu

96 odium inui infection on the performance of a simian immunodeficiency virus (SIV) DNA vaccine.

97 mmunization, or the capacity to neutralize a simian immunodeficiency virus (SIV) Env-expressing pseud

98 human immunodeficiency virus type 1 (HIV-1)/simian immunodeficiency virus (SIV) envelope spike (Env)

99 tructurally conserved parts of the HIV-1 and simian immunodeficiency virus (SIV) Envs.

100 ural-host sooty mangabeys (SM) infected with simian immunodeficiency virus (SIV) exhibit high viral l

101 nt study, we found that protection following simian immunodeficiency virus (SIV) exposure correlated

102 TANCE Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) express a small prot

103 lymorphism limits and complicates the use of simian immunodeficiency virus (SIV) for evaluation of hu

104 We deep sequenced simian immunodeficiency virus (SIV) from Mauritian cynom

105 s Indiana serotype (rVSIV) vector expressing simian immunodeficiency virus (SIV) gag and human immuno

106 When we introduced the simian immunodeficiency virus (SIV) gag gene into severa

107 L. monocytogenes elicited more potent simian immunodeficiency virus (SIV) Gag-specific CD8(+)

108 ycobacterium tuberculosis strains expressing simian immunodeficiency virus (SIV) genes safely induces

109 an immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) gp120 exterior envel

110 ons.IMPORTANCE Rhesus macaque infection with simian immunodeficiency virus (SIV) has served as an imp

111 ts of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) have been described

112 an immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) have evolved the Vif

113 African-origin, natural simian immunodeficiency virus (SIV) hosts do not typical

114 -1)-infected humans, African-origin, natural simian immunodeficiency virus (SIV) hosts, such as Afric

115 n immunodeficiency virus (HIV) in humans and simian immunodeficiency virus (SIV) in macaques (MAC) le

116 ents that utilize live attenuated strains of simian immunodeficiency virus (SIV) in monkeys may be us

117 a vaccine to protect against acquisition of simian immunodeficiency virus (SIV) in vaccinated rhesus

118 on of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) in vivo is well esta

119 an immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) in vivo.

120 GI) tract of Asian macaques with progressive simian immunodeficiency virus (SIV) infection and humans

121 erable to human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) infection and thus a

122 Human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) infection causes B-c

123 HIV/simian immunodeficiency virus (SIV) infection causes bre

124 The time to acquisition of simian immunodeficiency virus (SIV) infection following

125 target cell recruitment and establishment of simian immunodeficiency virus (SIV) infection following

126 The development of AIDS in chronic HIV/simian immunodeficiency virus (SIV) infection has been c

127 in chronic human immunodeficiency virus and simian immunodeficiency virus (SIV) infection has been r

128 ght contribute to the asymptomatic nature of simian immunodeficiency virus (SIV) infection in its nat

129 Simian immunodeficiency virus (SIV) infection in macaque

130 f cytokine-producing NK cells during primary simian immunodeficiency virus (SIV) infection in Mamu-A*

131 re changes in mucosal IL-10 signaling during simian immunodeficiency virus (SIV) infection in rhesus

132 tor (GM-CSF) by CD8(+) T cells 21 days after simian immunodeficiency virus (SIV) infection in rhesus

133 n genes that show a response to experimental simian immunodeficiency virus (SIV) infection in vervet

134 Pathogenic simian immunodeficiency virus (SIV) infection is associa

135 AIDS caused by simian immunodeficiency virus (SIV) infection is associa

136 re we studied progressive and nonprogressive simian immunodeficiency virus (SIV) infection models in

137 age proliferation occurs in the brain during simian immunodeficiency virus (SIV) infection of adult m

138 Studies of natural, nonpathogenic simian immunodeficiency virus (SIV) infection of African

139 Simian immunodeficiency virus (SIV) infection of macaque

140 Simian immunodeficiency virus (SIV) infection of natural

141 al reservoir is seeded rapidly after mucosal simian immunodeficiency virus (SIV) infection of rhesus

142 Here we show that simian immunodeficiency virus (SIV) infection of rhesus

143 Simian immunodeficiency virus (SIV) infection of rhesus

144 Simian immunodeficiency virus (SIV) infection of rhesus

145 Comparison of the immunologic effects of simian immunodeficiency virus (SIV) infection on rhesus

146 Human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) infection results in

147 During acute simian immunodeficiency virus (SIV) infection, gut homin

148 n pathways involved in establishing systemic simian immunodeficiency virus (SIV) infection, we necrop

149 from a Tat-inducible promoter upon HIV-1 or simian immunodeficiency virus (SIV) infection.

150 ing acute human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) infection.

151 mation and gut immune dysfunction during the simian immunodeficiency virus (SIV) infection.

152 on during human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) infection.

153 ospinal fluid of rhesus monkeys with chronic simian immunodeficiency virus (SIV) infection.

154 isposed to more pathogenic manifestations of simian immunodeficiency virus (SIV) infection.

155 Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infections induce ro

156 uring human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infections.

157 Currently available simian immunodeficiency virus (SIV) infectious molecular

158 A subtype C isolate was similar, while a simian immunodeficiency virus (SIV) isolate showed signi

159 different human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) lentiviruses.

160 replication of the highly pathogenic clonal simian immunodeficiency virus (SIV) mac239 virus.

161 ine oxidase (MAO) activity in the brain of a simian immunodeficiency virus (SIV) model of human immun

162 Nonhuman primate-simian immunodeficiency virus (SIV) models are powerful

163 Findings obtained with the simian immunodeficiency virus (SIV) monkey model have pr

164 Studies in both humans and simian immunodeficiency virus (SIV) monkey models have i

165 an immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) must be maintained i

166 antagonism of monkey and great ape BST-2 by simian immunodeficiency virus (SIV) Nef.

167 inical challenge studies have used cell-free simian immunodeficiency virus (SIV) or simian/human immu

168 8 Env can be incorporated into HIV-1 but not simian immunodeficiency virus (SIV) particles.

169 tissue (GALT) and have a key role in HIV and simian immunodeficiency virus (SIV) pathogenesis.

170 an immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) populations in vivo

171 Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) primarily infect act

172 ic virus genome and to express an attenuated simian immunodeficiency virus (SIV) protease for particl

173 We found that simian immunodeficiency virus (SIV) protein-expressing r

174 ) lymphocyte-depleted macaques infected with simian immunodeficiency virus (SIV) provide an increasin

175 is of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) reflects a balance b

176 Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) replication in human

177 Chronic-phase HIV and simian immunodeficiency virus (SIV) replication is reduc

178 ions, human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) replication may cont

179 We developed a method to capture total-body simian immunodeficiency virus (SIV) replication using im

180 also predisposes rhesus macaques to control simian immunodeficiency virus (SIV) replication.

181 of early human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) replication.

182 vaccinated macaques dramatically suppressed simian immunodeficiency virus (SIV) replication: peak vi

183 sruption of the conserved motif GYxxO in the simian immunodeficiency virus (SIV) SIVmac239 envelope (

184 l for HIV research; however, the dynamics of simian immunodeficiency virus (SIV) SIVmac239 infection

185 The live attenuated simian immunodeficiency virus (SIV) SIVmac239Deltanef is

186 rarectal inoculation of rhesus macaques with simian immunodeficiency virus (SIV) SIVmac251 to examine

187 d in all primate lentiviruses, and its HIV-2/simian immunodeficiency virus (SIV) SIVsm paralogue Vpx,

188 Simian immunodeficiency virus (SIV) stocks for in vivo n

189 The sooty mangabey-derived simian immunodeficiency virus (SIV) strain E660 (SIVsmE6

190 f male rhesus macaques (RMs) inoculated with simian immunodeficiency virus (SIV) strain SIVmac251 by

191 Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) strains differ in th

192 The lentiviruses HIV and simian immunodeficiency virus (SIV) subvert intracellula

193 HIV and simian immunodeficiency virus (SIV) target CD4(+) T cell

194 abeys (SM) are well-studied natural hosts of simian immunodeficiency virus (SIV) that do not progress

195 e have successfully isolated a new strain of simian immunodeficiency virus (SIV) that is capable of e

196 g in rhesus macaques (Macaca mulatta) during simian immunodeficiency virus (SIV) transmission and acu

197 ate AIDS vaccine can provide protection from simian immunodeficiency virus (SIV) transmission and dis

198 r entering a host cell, retroviruses such as simian immunodeficiency virus (SIV) uncoat, disassemblin

199 ted DNA/modified vaccinia virus Ankara (MVA) simian immunodeficiency virus (SIV) vaccine enhances pro

200 alization sieve effect in a nonhuman primate simian immunodeficiency virus (SIV) vaccine trial (DNA p

201 echanistic insights into how live attenuated simian immunodeficiency virus (SIV) vaccines (LAVs) can

202 Live attenuated simian immunodeficiency virus (SIV) vaccines (LAVs) rema

203 Working with the macaque simian immunodeficiency virus (SIV) vaginal challenge mo

204 o evaluate antibody specificities induced by simian immunodeficiency virus (SIV) versus human immunod

205 an immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) viral infectivity fa

206 striction factor SAMHD1 using Vpx-containing simian immunodeficiency virus (SIV) virion-like particle

207 an immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) virions with protein

208 HIV-1 Vpr and HIV-2/simian immunodeficiency virus (SIV) Vpr and Vpx engage t

209 ned the G2/M arrest phenotypes of a panel of simian immunodeficiency virus (SIV) Vpr proteins.

210 20 of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) was investigated for

211 Simian immunodeficiency virus (SIV) was nontraumatically

212 (HIV) emergence following human exposures to simian immunodeficiency virus (SIV), an understanding of

213 keys are susceptible to infection by HIV and simian immunodeficiency virus (SIV), and are considered

214 sory proteins of primate lentiviruses HIV-1, simian immunodeficiency virus (SIV), and BIV all form ub

215 can green monkeys (AGM) are natural hosts of simian immunodeficiency virus (SIV), and infection in th

216 ally" occurring pathogens, such as Ebola and Simian Immunodeficiency Virus (SIV), and respiratory pat

217 quely valuable for genetic investigations of simian immunodeficiency virus (SIV), for which it is the

218 mulated with a vaccine regimen that includes simian immunodeficiency virus (SIV), interleukin 2 (IL-2

219 sum A1 partially inhibited HIV-1, as well as simian immunodeficiency virus (SIV), murine leukemia vir

220 nhuman primates were coinfected with Mtb and simian immunodeficiency virus (SIV), recapitulating huma

221 Studies of natural HIV-1 infection, simian immunodeficiency virus (SIV)- or simian-human imm

222 orescence microscopy thoracic aortas from 16 simian immunodeficiency virus (SIV)- or simian-human imm

223 To this end, preclinical simian immunodeficiency virus (SIV)-based nonhuman prima

224 ere validated in archival brain tissues from Simian Immunodeficiency Virus (SIV)-infected and uninfec

225 irus-specific cell-mediated immunity in both simian immunodeficiency virus (SIV)-infected and uninfec

226 ts were detectable, but increased 20-fold in simian immunodeficiency virus (SIV)-infected animals.

227 ejuna, and livers of healthy and chronically simian immunodeficiency virus (SIV)-infected Asian macaq

228 iciency virus (HIV)-infected individuals and simian immunodeficiency virus (SIV)-infected Asian macaq

229 fected monocytes and macrophages to HIV- and simian immunodeficiency virus (SIV)-infected cells in vi

230 re loss of lean body mass and body weight in simian immunodeficiency virus (SIV)-infected juvenile rh

231 In simian immunodeficiency virus (SIV)-infected macaques, c

232 escape-associated compensatory mutations in simian immunodeficiency virus (SIV)-infected macaques.

233 of T cell subsets in the liver in normal and simian immunodeficiency virus (SIV)-infected macaques.

234 Using the simian immunodeficiency virus (SIV)-infected nonhuman pr

235 alleles likely affect viral diversity in the simian immunodeficiency virus (SIV)-infected pig-tailed

236 A chronic ethanol feeding model in simian immunodeficiency virus (SIV)-infected rhesus maca

237 dictates the tempo of progression to AIDS in simian immunodeficiency virus (SIV)-infected rhesus maca

238 In a previous study, we found that in simian immunodeficiency virus (SIV)-infected rhesus maca

239 Antiretroviral-treated, chronically simian immunodeficiency virus (SIV)-infected rhesus maca

240 body-mediated CD8(+) lymphocyte depletion in simian immunodeficiency virus (SIV)-infected rhesus maca

241 s system (CNS) has not yet been reached, the simian immunodeficiency virus (SIV)-infected rhesus maca

242 ), and it is capable of inducing diseases in simian immunodeficiency virus (SIV)-infected RM that are

243 Simian immunodeficiency virus (SIV)-infected sooty manga

244 cells or purified CD4(+) T cells from HIV or simian immunodeficiency virus (SIV)-infected subjects wi

245 Using the simian immunodeficiency virus (SIV)-macaque model, we te

246 iva, and urine were evaluated in a cohort of simian immunodeficiency virus (SIV)-negative rhesus maca

247 Using a rhesus macaque model of simian immunodeficiency virus (SIV)-Plasmodium fragile c

248 Here, we show a population of simian immunodeficiency virus (SIV)-specific CD8 T cells

249 Simian immunodeficiency virus (SIV)-specific CD8(+) T ce

250 Human immunodeficiency virus (HIV)- and simian immunodeficiency virus (SIV)-specific CD8(+) T ce

251 erons, and impaired response to infection by simian immunodeficiency virus (SIV).

252 ains including clinical isolates, as well as simian immunodeficiency virus (SIV).

253 used a nonhuman primate challenge model with simian immunodeficiency virus (SIV).

254 t they are not natural hosts of HIV-1 or any simian immunodeficiency virus (SIV).

255 it is largely dispensable for replication of simian immunodeficiency virus (SIV).

256 tion of Env defines pathogenic properties of simian immunodeficiency virus (SIV).

257 are each naturally infected with a distinct simian immunodeficiency virus (SIV).

258 ants in inducing protective immunity against simian immunodeficiency virus (SIV).

259 monkeys (AGMs) are natural primate hosts of simian immunodeficiency virus (SIV).

260 ian-human immunodeficiency virus (SHIV), and simian immunodeficiency virus (SIV).

261 on by human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV).

262 noculation (days postinoculation [dpi]) with simian immunodeficiency virus (SIV).

263 ol of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV).

264 ) T cell activation, the main cell target of simian immunodeficiency virus (SIV)/HIV.

265 Chimeric simian immunodeficiency virus (SIV)/human immunodeficien

266 al, nasal, and vaginal vaccinations with DNA simian immunodeficiency virus (SIV)/interleukin-2 (IL-2)

267 ction, or increased platelet activation in a simian immunodeficiency virus (SIV)/macaque model.

268 Using the simian immunodeficiency virus (SIV)/rhesus monkey model

269 hanisms, we found that p21 impairs HIV-1 and simian immunodeficiency virus (SIV)mac reverse transcrip

270 n new rYF17D viruses expressing fragments of simian immunodeficiency virus (SIV)mac239 Gag, Nef, and

271 Nonhuman primate natural hosts for simian immunodeficiency viruses (SIV) develop a nonresol

272 re targeted by primate lentiviruses (HIV and simian immunodeficiency virus [SIV]) are of intense inte

273 an immunodeficiency virus type 1 [HIV-1] and simian immunodeficiency virus [SIV]) if its activity is

274 f proteins of HIV-1 and African green monkey simian immunodeficiency virus (SIVagm) bind residue 128

275 monkeys (AGMs) are naturally infected with a simian immunodeficiency virus (SIVagm) that is nonpathog

276 Ms; genus Chlorocebus) are a natural host of simian immunodeficiency virus (SIVAGM).

277 an green monkeys (AGMs) are natural hosts of simian immunodeficiency virus (SIVAGM).

278 e detected in the blood of Gambian primates: simian immunodeficiency virus (SIVagm; in 42% of animals

279 etherin, is associated with the evolution of simian immunodeficiency virus (SIVcpz) into pandemic gro

280 atched SIV envelope (Env) gene, derived from simian immunodeficiency virus SIVmac239, prevents infect

281 show analogous, robust antibody responses in simian immunodeficiency virus SIVmac239-infected rhesus

282 ranules by cytolytic NK cells during primary simian immunodeficiency virus SIVmac251 infection.

283 While simian immunodeficiency viruses (SIVs) are generally non

284 Lentiviruses such as HIV-2 and some simian immunodeficiency viruses (SIVs) counteract the re

285 an immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency viruses (SIVs) evolved through t

286 lentiviruses reveals that several species of simian immunodeficiency viruses (SIVs) have lost the gly

287 onhuman primates are naturally infected with simian immunodeficiency viruses (SIVs) in the wild and i

288 ependent cross-species transmission event of simian immunodeficiency viruses (SIVs) infecting African

289 singly, however, the Vpu proteins encoded by simian immunodeficiency viruses (SIVs) of African guenon

290 Simian immunodeficiency viruses (SIVs) use their Nef pro

291 er lentiviruses, including HIV-2 and related simian immunodeficiency viruses (SIVs), SAMHD1 restricti

292 es, despite extensive sequencing of HIVs and simian immunodeficiency viruses (SIVs).

293 Simian immunodeficiency virus SIVsab infection is comple

294 ural host sooty mangabeys (SM) infected with simian immunodeficiency virus SIVsmm do not develop AIDS

295 rus serotype 5 (rAd5) boost vaccination with simian immunodeficiency virus strain mac239 (SIVmac239)

296 from cross-species transmission of SIVcpz, a simian immunodeficiency virus that naturally infects chi

297 Studies of vaginal transmission of simian immunodeficiency virus to nonhuman primates (NHPs

298 h Nef is the viral gene product used by most simian immunodeficiency viruses to overcome restriction

299 We found that some simian immunodeficiency viruses use arrays of glutamine

300 Most simian immunodeficiency viruses use their Nef protein to